IP Library Granted Patent US 8,834,445
Granted Patent B2
US 8,834,445 · App. 13/436,288 · Granted Sep 16, 2014

Methods of treating or preventing peritonitis with oxidative reductive potential water solution

Inventors: Hojabr Alimi (Santa Rosa, CA); Andres Gutierrez (Petaluma, CA)
Assignee: Oculus Innovative Sciences, Inc.
A61K33/40A61K33/20A61K45/06A61K33/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,834,445
App. No.
13/436,288
Granted
Sep 16, 2014
Kind
B2
Abstract

Provided is a method for treating or preventing peritonitis by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents. Further provided is a method for preventing peritoneal hemorrhage, adhesions and abscesses.

Claims (24)

1. A method of preventing or treating peritonitis in a patient, the method comprising administering to the patient a therapeutically effective amount of an oxidative reductive potential water solution, wherein the solution comprises free chlorine species at a level of from about 10 ppm to about 200 ppm, wherein the solution is stable for at least two months, wherein the solution comprises anode water and cathode water, and wherein the solution has a pH of from about 6.4 to about 7.8, wherein the free chlorine species is selected from the group consisting of hypochlorous acid, hypochlorite ions, sodium hypochlorite, chloride ions, dissolved chlorine gas, and mixtures thereof.

2. The method of claim 1 , comprising contacting the peritoneal tissue in the patient with a therapeutically effective amount of the oxidative reductive potential water solution.

3. The method of claim 1 , comprising delivering a therapeutically effective amount of the oxidative reductive potential water solution to the patient's peritoneal space.

4. The method of claim 3 , wherein the oxidative reductive potential water solution is delivered to the patient's peritoneal space intra-operatively, laproscopically or transabdominally.

5. The method of claim 3 , comprising:

(a) gaining access to the peritoneal space in the patient;

(b) delivering to the peritoneal space from about 0.1 to about 10 L of the oxidative reductive potential water solution;

(c) allowing the oxidative reductive potential water solution to remain in the peritoneal space for a period of time sufficient to provide a therapeutic effect;

(d) optionally removing the oxidative reductive potential water solution; and

(e) optionally repeating steps (b)-(d).

6. The method of claim 1 , wherein the peritonitis results from surgery, appendicitis, acute cholecystitis, peptic ulcer, diverticulitis, bowel obstruction, pancreatitis, pelvic inflammatory disease, mesenteric thrombosis, tumor, penetrating trauma, or a combination thereof.

7. The method of claim 1 , wherein the peritonitis is associated with an infection by one or more microorganisms selected from the group consisting of viruses, bacteria, and fungi.

8. The method of claim 7 , wherein the infection is by one or more bacteria selected from the group consisting of Pseudomonas aeruginosa, Escherichia coli, Enterococcus hirae, Acinetobacter baumannii, Acinetobacter species, Bacteroides fragilis, Enterobacter aerogenes, Enterococcus faecalis , Vancomycin resistant- Enterococcus faecium (VRE, MDR), Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Micrococcus luteus, Proteus mirabilis, Serratia marcescens, Staphylococcus aureus , Methicilin resistant- Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus pyogenes, Salmonella choleraesuis, Shigella dysenteriae, C. perfingens, Neisseria gonorrhea, Chlamydia trachomatis, Mycobaterium bovis, Chlamydia trachomatis , and combinations thereof.

9. The method of claim 7 , wherein the infection is by one or more fungi selected from the group consisting of Candida albicans, Candida parapsilasis, Candida tropicalis, Trichophyton mentagrophytes and Aspergillus fumigaus.

10. The method of claim 1 , further comprising administering to the patient a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of anti-infective agents and anti-inflammatory agents.

11. The method of claim 1 , wherein the pH of the oxidative reductive potential water solution is from about 7.4 to about 7.6.

12. The method of claim 1 , wherein the oxidative reductive potential water solution comprises cathode water in an amount of from about 10% to about 50% by volume of the solution, and anode water in an amount of from about 50% to about 90% by volume of the solution.

13. The method of claim 1 , wherein the solution comprises free chlorine species at a level of from about 50 ppm to about 80 ppm.

14. The method of claim 1 , wherein the free chlorine species comprises from about 15 ppm to about 35 ppm hypochlorous acid.

15. The method of claim 1 , wherein the free chlorine species comprises from about 25 ppm to about 50 ppm sodium hypochlorite.

16. The method of claim 1 , wherein the free chlorine species comprises from about 15 ppm to about 35 ppm hypochlorous acid and from about 25 ppm to about 50 ppm sodium hypochlorite.

17. A method of preventing peritoneal adhesions in a patient, the method comprising administering to the patient an oxidative reductive potential water solution in an amount effective to prevent peritoneal adhesions, wherein the solution comprises free chlorine species at a level of from about 10 ppm to about 200 ppm, wherein the solution is stable for at least two months, wherein the solution comprises anode water and cathode water, wherein the solution has a pH of from about 6.4 to about 7.8, and wherein the free chlorine species is selected from the group selected from the group consisting of hypochlorous acid, hypochlorite ions, sodium hypochlorite, chlorite ions, chloride ions, dissolved chlorine gas, and mixtures thereof.

18. A method of preventing peritoneal abscesses in a patient, the method comprising administering to the patient an oxidative reductive potential water solution in an amount effective to prevent peritoneal abscesses, wherein the solution comprises free chlorine species at a level of from about 10 ppm to about 200 ppm, wherein the solution is stable for at least two months, wherein the solution comprises anode water and cathode water, wherein the solution has a pH of from about 6.4 to about 7.8, and wherein the free chlorine species is selected from the group selected from the group consisting of hypochlorous acid, hypochlorite ions, sodium hypochlorite, chlorite ions, chloride ions, dissolved chlorine gas, and mixtures thereof.

19. A method of preventing systemic complications in a patient with peritonitis, the method comprising administering to the patient an oxidative reductive potential water solution in an amount effective to prevent peritoneal adhesions, wherein the solution comprises free chlorine species at a level of from about 10 ppm to about 200 ppm, wherein the solution is stable for at least two months, wherein the solution comprises anode water and cathode water, wherein the solution has a pH of from about 6.4 to about 7.8, and wherein the free chlorine species is selected from the group selected from the group consisting of hypochlorous acid, hypochlorite ions, sodium hypochlorite, chlorite ions, chloride ions, dissolved chlorine gas, and mixtures thereof.

Assignments (4)
CHANGE OF NAME Recorded Jan 5, 2017
From: OCULUS INNOVATIVE SCIENCES, INC.
To: SONOMA PHARMACEUTICALS, INC.
Reel/Frame 041257/0375 →
SECURITY AGREEMENT Recorded Apr 11, 2013
From: OCULUS INNOVATIVE SCIENCES, INC.
To: VENTURE LENDING & LEASING V, INC.
Reel/Frame 030202/0873 →
SECURITY AGREEMENT Recorded Apr 11, 2013
From: OCULUS INNOVATIVE SCIENCES, INC.
To: VENTURE LENDING & LEASING VI, INC.
Reel/Frame 030202/0892 →
SECURITY AGREEMENT Recorded Jul 25, 2012
From: OCULUS INNOVATIVE SCIENCES, INC.
To: VENTURE LENDING & LEASING VI, INC.; VENTURE LENDING & LEASING V, INC.
Reel/Frame 028634/0778 →
Continuity (6)
Continuation 11656328 · Jan 22, 2007
Provisional Application 60760635 · Jan 20, 2006
Provisional Application 60760567 · Jan 20, 2006
Provisional Application 60760645 · Jan 20, 2006
Provisional Application 60760557 · Jan 20, 2006
Related Publication 20120251631A1 · Oct 4, 2012